10-K/A - Celularity Inc (0001752828) (Filer)

Wed, May 21, 9:30 PM (28 days ago)

**Summary of Celularity Inc. (CELU) 10-K/A Amendment** **Company Overview:** Celularity Inc. (CELU) is a biotechnology company focused on cellular therapeutics. The amendment to the 10-K/A includes updates to Part III, Items 10, 11, 12, 13, and 14, along with Part IV, Item 15, and new certifications by the company's principal executive officers and principal financial officer. **Financial Performance:** - **Revenue and Net Income:** Not explicitly detailed in the provided text. - **Operating Expenses:** Not explicitly detailed in the provided text. - **Earnings Per Share (EPS):** Not explicitly detailed in the provided text. **Strategic Overview:** - **Executive and Director Compensation:** The amendment includes detailed information on the compensation of named executive officers and directors, including base salaries, bonuses, stock awards, and other compensation. - **Board Composition:** The board consists of five members, with Dr. Robert J. Hariri serving as Chairman and CEO. The board is divided into three classes, each serving staggered terms. - **Committees:** The board has established an audit committee, a compensation committee, and a nominating and corporate governance committee. **Future Outlook:** - **Risk Factors:** The company faces various risks, including financial risks associated with loans and related-party transactions. - **Financial Condition:** The company has entered into several loan agreements and related-party transactions, which are detailed in the amendment. - **Market Position Changes:** Not explicitly detailed in the provided text. **Risk Factors:** - **Financial Risks:** The company has significant debt obligations and related-party transactions, which could impact its financial stability. - **Operational Risks:** The company's operations are subject to regulatory and market risks, which could affect its ability to achieve its strategic goals. **Market Position Changes:** - **Competitive Landscape:** The company operates in a competitive biotechnology sector, and its market position is influenced by its ability to innovate and secure regulatory approvals. **Conclusion:** The amendment provides detailed updates on the company's governance, executive compensation, and financial condition. Investors should review the full amendment for a comprehensive understanding of Celularity Inc.'s financial health and strategic direction.